Cardio Flow

Executive Summary

Cardio Flow, Inc. is a private medical device company headquartered in Minneapolis, MN, focused on treating peripheral artery disease (PAD) with its FreedomFlow Orbital Atherectomy Platform. Founded in 2015, the company has developed a minimally invasive, catheter-based system designed to remove atherosclerotic plaque across a wide range of vessel diameters. The technology aims to offer physicians an efficient, flexible, and cost-effective alternative to existing atherectomy devices, potentially improving outcomes for complex PAD patients while reducing procedural costs. With a growing prevalence of PAD driven by aging populations and rising diabetes rates, Cardio Flow is positioned in a sizable and expanding market. The company’s platform has the potential to differentiate through its orbital mechanism, which may enhance safety and efficacy compared to directional or rotational atherectomy. While Cardio Flow is already commercializing its product, the company remains private with limited public data on revenue or funding. Key near-term opportunities include expanding indications to coronary arteries or larger vessels, securing additional distribution partnerships, and generating clinical evidence to support broader adoption. With a focused product line and a seasoned medical device hub in Minneapolis, Cardio Flow could be an attractive acquisition target for larger cardiovascular companies seeking to bolster their PAD portfolio.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for coronary artery indication50% success
• Q3 2026Strategic partnership or distribution deal with major cardiovascular firm60% success
• Q4 2026Publication of pivotal clinical trial data demonstrating superiority over balloon angioplasty40% success